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Abstract: Background: Extensive surgical resection remains nowadays the best 
treatment available for most brain tumours. Perioperative outcomes following surgery 
for brain tumors are an important indicator of the safety as well as efficacy of surgical 
intervention. The goal of this study was to review the results of surgical treatment in our 
Department, run by a single neurosurgeon, in order to quantify morbidity and mortality 
and determine predictive risk factors for each patient. Materials and Methods: A total of 
Three hundred patients undergoing various surgeries for brain tumors were analyzed. 
Routine surgical techniques and uniform antibiotic policy were used. Navigation 
advanced operating microscope/ intraoperative electrophysiological monitoring was not 
available. The endpoints assessed included immediate postoperative neurological status, 
neurological outcome at discharge, regional complications, systemic complications, 
overall morbidity, and mortality. Various risk factors assessed included clinico-
epidemiological factors, tumor-related factors, and surgery-related factors. Results: 
Median age was 36.37 years. 74.3% had tumors larger than 4 cm. Neurological morbidity, 
and regional and systemic complications occurred in 14.3, 14.3, and 11.3%, respectively. 
Overall, major morbidity occurred in 14.3% and perioperative mortality rate was 3.3%. 
Conclusions: Our patients were younger and had larger tumors than were generally 
reported. Despite the unavailability of advanced intraoperative aids, we could achieve 
acceptable levels of morbidity and mortality rates. The knowledge of the complications 
rate in each particular neurosurgical department turns out essentially to provide the 
patient with tailored information about risks before surgery. 
Key words: Brain tumors, neurological outcomes, perioperative outcomes, surgical 
complications 
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Introduction 
Outcome assessment is an important part 
of evaluation of any form of therapy. Neuro-
oncology has evolved into a specialty in its own 
right, with dedicated neuro-oncology services 
providing neurologically well preserved. The 
possible advantages of surgery have to be 
weighed against the comprehensive care for 
patients with brain tumors.[1] Surgery oftenly 
remains the primary form of treatment for 
various brain tumors. While on one side, there 
is unequivocal evidence of the survival benefit 
of radical resection of tumors[2-8], on the 
other hand it is important to preserve and 
possibly restore neurological function. In the 
current era, there has been an increase in the 
early detection of tumors due to advancement 
in imaging technology, especially at a stage 
when the patient may be potential risks 
involved,[2] which are often the limiting factor 
in radical surgery. Majority of the 
neurosurgeons today follow the principle of 
‘safe maximal resection’. Newer technology 
such as navigation, intraoperative imaging, 
and intraoperative monitoring helps 
neurosurgeons to achieve these goals. The 
goals, when dealing with the tumor, are 
twofold — a long-term goal of oncological 
control (reflected in the progression-free, 
disease-free, and overall survival); and the 
short-term goal of ensuring minimal therapy-
related toxicity (which in the context of 
surgery would translate into immediate 
Perioperative outcomes). As the option of 
surgery is very crucial in the control of CNS 
tumors (especially gliomas), systematic and 
objective documentation of Perioperative 
outcomes is important. Not only does it 
provide a baseline data for a centre, which can 
be very useful for patient counselling with 
regard to the risks of surgery (which may vary 
from centre to centre), but also allows a 
particular centre to objectively assess the 
benefits of introduction of new technology. 
Adding to that, it helps in comparison across 
various centres, especially when large 
multicentric trials are conducted, especially 
relevant for developing countries where 
resources are limited, with an aim to 
compensate cost-constrained infrastructure 
and at the same time providing satisfactory 
results. Our department, consisting of single 
neurosurgeon, is at the Government Medical 
college,Kota, Rajasthan, which is a tertiary care 
centre rendering medical services to a large 
population of south-east Rajasthan. This 
article is an attempt to objectively document 
the Perioperative outcomes after surgeries for 
different brain tumors. 
Materials and methods 
This observational study was conducted at 
the department of Neurosurgery at 
Government Medical College, Kota, 
Rajasthan. All the patients who underwent 
surgery for all types of brain tumors over a 
period of 4 years (2013 – 2017) were included. 
During surgeries, standard neurosurgical 
principles were followed. No intraoperative 
monitoring tools (navigation, microscope, 
intraoperative imaging, and intraoperative 
monitoring) were available during this time 
period. A uniform policy of antibiotic 
prophylaxis (single dose Perioperative second 
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or third generation cephalosporin) was 
applied. All patients were operated under a 
Perioperative cover of manitol and 
corticosteroids (dexamethasone), which was 
tapered postoperatively. Antiepileptic 
medications were used in all patients 
perioperatively. Non-pharmacological deep 
venous thrombosis prophylaxis, in the form of 
intermittent pneumatic compression devices 
and thrombo-elastic devices (stockings) were 
utilized with pharmacological prophylaxis 
(heparin or low-molecular weight heparins) 
reserved for patients with anticipated 
prolonged recumbence. 
The outcome measures assessed included 
immediate postoperative (first 24 hours) 
neurological status, neurological status at 
discharge, regional complications, systemic 
complications, overall morbidity, and 
Perioperative mortality. The neurological 
status at each time point was recorded as same, 
improved, or worse as compared to the 
immediate previous assessment. It was further 
categorized as per severity into minor 
(minimal alteration of function) or major 
(significant alteration in function), as well as in 
terms of duration, as transient (completely or 
significantly reversible by the time of 
discharge) or prolonged (minimal or no 
improvement till the time of discharge). 
Regional complications included the presence 
of significant operative site hematoma, 
worsening or new onset seizures, as well as 
wound-related complications (which included 
wound collection, gape, leak, and surgical site 
infection defined as per the Centres for 
Disease Control (CDC) criteria [9]). The 
systemic complications included all other 
complications such as metabolic disturbances, 
hemodynamic complications, systemic 
infections, and coagulopathy. The overall 
morbidity as well as mortality (at the time of 
discharge) was also recorded. For each of the 
endpoints mentioned various potential risk 
factors were assessed. These included 
preoperative predictors (clinico-
epidemiological characteristics, such as, age, 
gender, preoperative neurological status, 
altered sensorium, KPS score, prior treatment 
history, comorbid illnesses), surgery-related 
variables (infra- or supratentorial, emergency 
surgery, duration of surgery [more than or less 
than four hours], head shaving, use of wound 
drain, and the extent of resection [subjectively 
based on surgeon’s impression and 
postoperative CT scans]), as well as tumor-
related factors (size [single largest dimension 
more than or less than 4 cm], location, and 
histology). This analysis was performed for the 
whole set of patients as well as for the subset of 
gliomas (n = 152) as well as glioblastomas (n = 
65).  
For the purpose of statistical analysis, the risk 
factors were dichotomized as shown in Table 1. 
The endpoints were also dichotomized to denote 
the presence or absence of a particular 
complication. For neurological outcomes, 
improvements and no change were considered 
as favorable outcomes, whereas, worsening was 
considered as a complication for uni- and 
multivariate analysis.  
Results 
During the study period, a total of 300 
surgeries were done for brain tumors. Mean 
age of all the patients was 36.37 years. Male: 
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female ratio was 1.3:1(Table 1).  Out of all the 
patients, 152 patients (50.6%) had glial tumors 
while rest of the patients had non-glial tumors 
including embryonal tumors and metastasis 
(Table 2).The overall complications 
encountered are as summarized in Table 4. 
Two hundred and fifty-one patients (83.7%) 
remained the same neurologically (n = 84 
[28%]) or had improved (n = 167 [55.7%]) 
postoperatively. Of the 84 who remained the 
same, only six had improved further till the 
time of discharge and three had died due to 
other complications. On the other hand, of the 
167 with immediate postoperative 
improvement, 53 further improved till 
discharge. Thus, neurological improvement 
was seen in the immediate postoperative 
period and was a dynamically sustained 
phenomenon in those that improved, evolving 
over the postoperative period. At the same 
time neurological worsening was encountered 
in 49 (16.3%), of whom one-third (n=16) had 
minor deficits (all being transient except one) 
and two-thirds (n = 33) suffered major deficits 
(only six improved till discharge). Comparing 
the postoperative neurological outcomes with 
the preoperative neurological status revealed 
that of the 52 (17.6%) preoperative, 
neurologically normal patients, ninteen (6.1%) 
experienced postoperative worsening (6 being 
minor deficits, 3 of which were transient, and 
10 were major, of which two were transient). 
There was no mortality in this group. Of the 
248 (82.6%) patients with preoperative 
neurological deficits, 98 (32.6%) remained the 
same, 110 (36.6%) had improved, whereas, 30 
(10%) worsened. All ten patients who died 
were from this subgroup. 
Regional complications were encountered 
in 14.3% patients [Table 4]. Of these, wound-
related complications were the major 
contributors (10.6%), with surgical site 
infections predominating (6.6%). Systemic 
complications occurred in 11.3%, the majority 
being metabolic disturbances (hyponatremia 
commonly), most of which were reversible. 
Clinically significant coagulopathy occurred 
in only 2%. 
 Although neurological worsening (16.3%) 
was an important contributor to the overall 
morbidity (39.9%), it is evident from Table 6 
that other postoperative complications 
(regional and systemic) were significant 
contributors (if not more) to the overall 
outcomes. In fact22.6% of those with no 
neurological morbidity sustained some other 
form of morbidity in the postoperative period 
[Table 4]. 
The average duration of postoperative stay 
was 9.2 days (7.2 days for those with no 
morbidity and 12.4 days for those with some 
postoperative complication).Ten patients died 
in the postoperative period. The details of the 
cause of death are depicted in Table 5. 
Various risk factors were analyzed for each 
complication [Table 3]. All the possible factors 
were initially tested in a univariate analysis 
[Table 3].On univariate analysis none of the 
risk factors were significant for immediate 
postoperative neurological status or regional 
complications. Patients with preoperative 
neurological deficits and those undergoing 
emergency surgery were more likely to have 
systemic complications. Age less than 18 years 
and emergency surgery were predictive of 
increased morbidity and mortality. In 
addition, the presence of preoperative altered 
sensorium was predictive of higher 
perioperative mortality.  
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TABLE 1 
Age and sex wise distribution of all the 
patients 
 Brain Tumors 
Age Range (years) Males Females Total 
<5 14 07 21 
5 - <20 26 19 45 
20 - <60 94 78 172 
>60 36 26 62 
TOTAL 170 130 300 
 
 
TABLE 2 
Histological spectrum of cases 
  Numbers Total 
Glial tumors Astrocytic tumors 96 152 (50.7%) 
 Oligodendroglial tumors 16
 
Ependymal tumors
Medulloblastoma
17
23
Non-glial tumors Metastases 13 148 (49.3%) 
 Embryonal tumors 12
 Meningioma                              53
 Schwannoma 21
 Others 49
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TABLE 3 
Demographic, clinical, surgical, and tumours type profile 
  Number Percent    
Demographic profile    
Age Median age (range)      36.37 years  
Gender Male / female 170 / 130 56.6 / 43.3 
Clinical features    
Pre-op. Neurological deficits Yes / No 248 / 52 82.7 / 17.3 
Pre-op. altered sensorium Yes / No 62 / 238 20.6 / 79.4 
KPS(Karnofsky Performance Scale) Median KPS 80  
 ≤ 70 / > 70 160 / 140 53.2/ 46.8 
Prior treatment Yes / No 04 / 296 1.3 / 98.7 
Surgical features    
Nature Emergency / elective 31 / 269 10.3 / 89.7 
Site Infratentorial / Supratentorial 117 / 183 38.9 / 61.1 
Duration of surgery Mean    4.1 hours  
 > 3 hours / ≤ 3 hours 136 / 164 45.4 / 54.6 
Extent of resection Gross total / subtotal 219 / 81 72.9 / 27.1 
Tumor-related features    
Tumor size > 4 cm / ≤ 4 cm 223 / 77 74.3 / 25.7 
Histology Glioma / others 152 / 148 50.7 / 49.3 
    
TABLE 4 
Postoperative complications 
Complications Number Percent 
   
Neurological worsening (overall) 49 16.3 
Minor 16 5.3 
Major 33 11 
Regional complications (overall) 43 14.3 
Wound-related 20 6.6 
Wound leak 6 2 
Wound gape 6 2 
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Meningitis 3 1 
Other (collection, 6 2 
pseudomeningoceles)   
Significant operative site 13 4.3 
Hematoma   
New / increased seizures 9 3 
Systemic complications (overall) 34 11.3 
Coagulopathy 6 2 
Hemodynamic 6 2 
Metabolic 22 7.3 
Other complications 34 11.3 
Re-exploration 02 0.6 
Morbidity (overall) 112 37.3 
Minor 69 23 
Major 43 14.3 
Mortality 10 3.3 
 
TABLE 5 
Details of perioperative mortality 
Clinical details Tumor Postoperative events    
 
74/ M, presented with focal 
deficits Bifrontal GBM 
Postoperative metabolic and 
multisystem failure 
16 / M with raised ICP Recurrent Craniopharyngioma Metabolic disturbance 
 30 / M with ataxia CP angle Schwanoma
Post-operative thrombocytopenia with 
hematoma
1 / M with altered sensorium Posterior fossa Medulloblasoma Brainstem dysfunction with aspiration 
8 / M with  ataxia Medulloblastoma Hydrocephalus and coning 
39 / F in altered sensorium Metastasis from adenocarcinoma Progressive coning 
28 / M altered sensorium Large petroclival meningioma Progressive coning 
24/F  with raised ICP                            Large left parasagital  meningioma              Progressive coning 
38/F with ataxia                                     Posterior fossa meningioma                           Brainstem dysfunction with aspiration 
70/M altered sensorium                        Metastasis from adenocarcinoma                 Postoperative metabolic and  
  multisystem failure 
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TABLE 6 
Comparative analysis of patient characteristics and perioperative outcomes in selected series of intra-
axial tumors 
 Sawaya10, 
Brell11, 
2000 
GOP study17, 2005 
(multicentric) 
Rabadan13, 
2007 
Moiyadi16  2010 
Present 
Study, 
2017 
Primary Recurrent
All 
intra-
axial Gliomas GBM 
All 
Number cases (years) 
400 
(2 years) 
200 
(6 years) 408 91 
236 
(6 years) 
196 
(3 
years) 130 65 
300 
( 4 years)
Histology (gliomas / 
mets / 
others) 
206 / 194 
/ 0 
166 / 34 / 
0 408 / 0 / 0 91 / 0 / 0 168 / 65 / 3 
130 / 
38/ 28 - - 
152/13/49 
Site (supra / 
infratentorial) 358 / 42 181 / 19 - - 220 / 16 166 / 30 - - 
183  / 117 
Median age 48 
51.7 
(mean) 55 50 51 38 38  
36.37 
Median KPS 80 - 90 80 
 (selected only 
those> 60) 80   
80 
- 
- 
Prior treatment (%) 38 - - 100 - 31.6   1.3 
T size > 4 cm (%) - - 56 55 - 71.9   74.3 
Gross total (> 90%) 
resection (%) 73 66 56 54 64 71.4   
72.9 
Morbidity 
(%)  
Overall 32 - 24.2 32.6 18.9 38.8 32.3 37 39.9
Major 13 27.5 - - - 17.9 17.8 21.5 
14.3 
Neurological 
outcome (%) 
Worsening
10 (8.5 
major) 
20.5 
(all major)
18.5% KPS
worsening 8      18 
14.5 
(11.5 major) 
8% KPS 
worsening 
16.8 
(11.2 
major)
17 
(12.3 
major) 
20 
(17 
major) 
16.3 
 
 
 
Same / 
improved 90  92 82  83.2 83 80 
83.7 
- 
Regional (%) 7 16 (major) 10 13 
Combined 
with 
neurological 
outcome 
17.3 
(all) 18 27 
14.3 
 
 
 
Systemic (%) 7.7 
4.5 
(major) 9.2 8.7 4.5 10.7 11.5 14 
11.3 
Mortality (%) 1.7 2.5 1.5 2.2 2.9 3.6 2.3 1.5 3.3 
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Discussion 
Perioperative outcomes are a measure of 
the short-term efficacy (neurological 
improvement and symptomatic relief) as well 
as the toxicity (perioperative morbidity and 
mortality) of a surgical intervention. With the 
use of multimodality therapy in the 
management of brain tumors it is very 
important to not only separate tumor-related 
and treatment-related effects, but also to 
identify the contributions of various treatment 
modalities toward treatment-related effects. 
For example neurological deficits (especially 
cognitive) in patients with supratentorial 
malignant gliomas could be due to the tumor 
itself, or as a result of surgery, or a 
consequence of radiotherapy. Appropriate 
evaluation at various relevant time points 
(including baseline) is essential. Moreover, 
this evaluation needs to be objective and 
uniformly reproducible. 
Early neurosurgeons were more concerned 
with saving lives and the focus was more on 
mortality reduction. With refinements in 
technique and advances in adjuncts, reduction 
in morbidity started being discussed. Since 
then, numerous studies have been published 
for intra-axial tumors.[10-13] There are, 
however, certain limitations that we would like 
to discuss. 
Study populations have been 
heterogeneous. Not only the clinical profile, 
but the tumor characteristics of apparently 
similar populations can be different [Table 6]. 
Our patients were significantly younger than 
those reported. Moreover, we had a much 
larger proportion of patients with big tumors. 
This we feel is probably because of the referral 
pattern at our centre, which drains a very large 
geographical region including remote and 
underserved areas, resulting in a significant 
time lag from the onset of symptoms to access 
to the necessary facilities and expertise. 
Although the influence of the preoperative 
tumor size on long-term outcomes is 
questionable, there is no doubt that larger 
tumors present a greater challenge during 
surgery and can adversely influence the 
perioperative outcomes. Moreover, it is likely 
that patients with larger tumors have raised 
intracranial pressure and altered neurological 
status, which was our experience too. 
Although the preoperative neurological status 
was a significant risk factor for overall 
morbidity and mortality on univariate 
analysis. This could be due to the small size of 
our series. 
Another problem in comparing with 
literature is the lack of uniformity in reporting 
risk factors and end-points. Most studies 
report the karnofsky performance scale (KPS) 
as a surrogate marker of clinical status. The 
KPS, although an objective assessment tool, 
has significant limitations. It may not reflect all 
the neurological deficits accurately and may 
often underestimate the neurological 
morbidity. Few of the studies have reported 
neurological worsening, but others have 
reported only changes in KPS. A small but 
definite and measurable neurological 
worsening may not reflect in the KPS. Others 
have used more specific neurological outcome 
scales such as the NIH Stroke Score.[14] 
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Nonetheless a scoring system, even as it 
ensures uniformity in measurement, tends to 
group outcomes and ignores small (but often 
clinically significant) differences. On the other 
hand the recording of individual neurological 
deficits may overestimate the neurological 
outcomes (both improvements as well as 
worsening). This (along with a more detailed 
reporting of regional complications in our 
series) may be a reason for the slightly 
increased overall morbidity we experienced. 
For documenting surgical site infection, we 
rigorously followed the CDC guidelines as part 
of a parallel prospective study, documenting 
wound infections in our service. Nonetheless, 
the major morbidity in our series still 
compared favorably [Table 6]. We believe that 
the neurological status more accurately 
reflected the patients’ clinical status and by 
meticulously documenting the status we were 
able to observe the temporal course of these 
deficits. Our results showed that neurological 
worsening (new deficits in 6.1% and 
aggravation of the existing deficits in 30%) was 
a significant issue; however, most of these 
deficits resolved by the time of discharge. This 
information was very crucial while counseling 
and preparing patients for surgery. Moreover, 
neurosurgeons should be cognizant of the fact 
that non-neurological morbidity was also a 
significant cause of postoperative 
complications.  Another important 
consideration was the resources available at 
various treating centers. Most reports were 
from western and developed nations, with 
access to the latest adjuncts and fewer cost 
constraints. During the period of the present 
analysis, we did not have navigation or 
intraoperative monitoring available. This was 
often the case with most resource-constrained 
centers in developing countries. Even as 
technological adjuncts definitely increased the 
surgeon’s comfort level during surgeries and 
possibly allowed more extensive resections to 
be performed safely, their role in objectively 
improving the perioperative outcomes 
remains debatable.[15] Our results showed 
that even without the use of such aids, 
acceptable outcomes could be achieved. Being 
a single center, single surgeon service allowed 
us to have a uniform perioperative 
management policy, along with a meticulously 
maintained, prospective, database-ensured, 
reliable data capture. However, sustained and 
regular documentation of such seemingly 
mundane data was crucial to generalize these 
results across similar centers across the world. 
Limitations of our study:  
Postoperative MR imaging for 
documenting residual disease was not always 
logistically possible, thus limiting objective 
volumetric assessment in all cases. Moreover, 
although we did attempt to assess individual 
risk factors, the relatively small size of our 
study group may not have accurately reflected 
the true association precluding the statistically 
significant results.  
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